Background. Breast cancer has the highest incidence of cancer in women. The first-line chemotherapy, Adriamycin-cyclophosphamide (AC) has good results, but its efficacy is not optimal. The fruit lectin substance Abelmoschus esculentus has an anti-cancer effect, so it is widely used as a chemotherapy supplement. The aim of the study is to prove Abelmoschus esculentus extract can increase the apoptotic index against chemotherapy
Method. In vivo laboratory trial study, we are using Sprague Dawley female rats aged 28 days with mammary adenocarcinoma induced by DMBA. There are 4 groups, namely; control (K): placebo, treatment1 (P1): AC chemotherapy (Adriamycin 1.5 mg and cyclophosphamide 15 mg), treatment2 (P2): Abelmoschus esculentus extract 150 mg/kgBB/day, and treatment3 (P3): a combination of AC and Abelmoschus esculentus extract.
Results. The P3 group had the highest levels of Endonuclease_G (EndoG) and apoptosis at (38.66 ± 0.73) and (21.03 ± 0.69), respectively. Combination of Abelmoschus esculentus extract with chemotherapeutic agents can improve the anticancer outcome by significantly increasing EndoG expression and apoptosis index (p<0.05) in comparison to other groups.
Conclusion. Extract from Abelmoschus esculentus fruit shows high apoptotic index and EndoG expression which means that this extract can increase the apoptotic response to in vivo in-cyclophosphamide adriamis chemotherapy.